Piper Jaffray Remains Neutral On ALNY In Advance Of ASCO Meeting

Piper Jaffray is maintaining its Neutral rating and its $10 price target on Alnylam Pharmaceuticals

as the company prepares to report at ASCO on June 4th. In the report, Piper Jaffray writes, “Abstracts were published last night for the upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago from June 3rd-7th. Alnylam is reporting Phase I data on ALN-VSP in liver cancer. Alnylam is the leading RNAi play; however we remain Neutral awaiting clinical progress and validation.” ALNY closed yesterday at $9.95.